Frank David 8/7/25 Frank David 8/7/25

How the FDA can score quick wins on transparency

The agency needs to organize its shambolic online collection of public documents.

Frank David 1/31/25 Frank David 1/31/25

A new take on developing drugs for chronic pain

Despite a recent failure, Lilly’s master protocol trial shows a path forward in chronic pain R&D.

Frank David 11/20/24 Frank David 11/20/24

Want to get up to speed on the biopharma biz? We’ve got you covered.

Frank David 5/1/19 Frank David 5/1/19

R&D portfolio strategy is so … unstrategic. Together with Navigant’s Greg Belogolovsky, we have some ideas to fix it.

Frank David 2/28/19 Frank David 2/28/19

As Jay-Z might say, breakthrough status may provide 99 benefits, but excess stock returns ain’t one.